Recombinant Human Epidermal Growth Factor Receptor 3 Fragment (CRP0891)
|Recombinant Human Epidermal Growth Factor Receptor 3 Fragment
- Product Overview
- Recombinant Human ErbB3 Fragment produced in E. coli is a single non-glycosylated fusion protein containing the extracellular domain of human ErbB3 fragment ( 190 amino acids, Met1-Cys190 )and having a molecular mass of 34kDa.
- Fully biologically active. Measured by its ability to postpone tumor emerge time of spontaneous breast cancer in FVB/N transgenic mice and inhibit the development of tumor, effectively inhibit the growth of in situ transplanted breast cancer in FVB/N transgenic mice.
- Less than 1EU/μg of rHuErbB3-f as determined by LAL method.
- >95% by SDS-PAGE and HPLC analyses.
- This liquid suspension is stable for several months at 0-4°C, but should be kept at -20°C for long term storage. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20°C to -70°C. Avoid repeated freeze/thaw cycles.
- It is recommended that sterile phosphate-buffered saline containing 1mg aluminum hydroxide be added to the vial to prepare a stock solution.
PDB rendering based on 1m6b.
- Antigen Description
- ErbB3, also called Her3 (human epidermal growth factor receptor 3), is a type I membrane glycoprotein that is a member of the ErbB family of tyrosine kinase receptors. ErbB family members serve as receptors for the epidermal growth factor (EGF) family of growth factors. Among ErbB family members, ErbB3 is unique in that it contains a defective kinase domain. ErbB3 is expressed in keratinocytes, melanocytes, skeletal muscle cells, embryonic myoblasts and Schwann cells. Monomeric ErbB3 serves as a low affinity receptor for the heregulins (HRG). rhErbB3-f is a recombinant genetic engineering product which expressed in E. Coli. RhErbB3-f can induce specific antibody production in vivo, hence to inhibit tumor cell growth. The product can be used to treat early, medium and advanced or post-operative breast cancer patients with over-expression of ErbB2. According to its mechanism of action, rhErbB3-f is classified into therapeutic cancer vaccine.
- ATP binding ; growth factor binding; nucleotide binding ; protein heterodimerization activity; protein homodimerization activity; protein tyrosine kinase activator activity; protein tyrosine kinase activity; transferase activity; transmembrane receptor activity; transmembrane receptor protein tyrosine kinase activity
- ErbB-3; HER3; MDA-BF-1; MGC88033; c-erbB-3; c-erbB3; erbB3-S; p180-ErbB3; p45-sErbB3; p85-sErbB3; EC 220.127.116.11; LCCS2; Receptor tyrosine-protein kinase erbB-3 precursor; Tyrosine kinase-type cell surface receptor HER3; lethal congenital contracture syndrome 2; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3; v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian)
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic or any in vivo human use.